Join to View Full Profile
10 E 102nd StNew York, NY 10029
Phone+1 212-241-7873
Dr. Richard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Shambavi Richard is an oncologist based in New York, NY, specializing in myeloproliferative disorders, bone marrow failure syndromes, aplastic anemia, multiple myeloma, and myelodysplastic syndromes. She completed her fellowship in Hematology and Medical Oncology at Montefiore Medical Center/Albert Einstein College of Medicine and her residency in Internal Medicine at BronxCare Health System. Dr. Richard is an author of several publications, including articles in "Blood Advances" and "Nature Cancer," focusing on multiple myeloma and related therapies. Her work has been cited by other publications, indicating her contributions to the field of oncology.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1997 - 1998
BronxCare Health SystemResidency, Internal Medicine, 1992 - 1995
Stanley Medical College SMCClass of 1988
Certifications & Licensure
NY State Medical License 1995 - 2026
NJ State Medical License 2004 - 2021
American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.Gliceida M Galarza Fortuna, Lauren Peres, Elena Nazarenko, Andre De Menezes Silva Corraes, Vanna N Hovanky
Blood Advances. 2025-12-09 - Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression.Junia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman, Tarek H Mouhieddine, Rocio Montes de Oca
Blood Advances. 2025-11-05 - Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.Beatrice M Razzo, Shonali Midha, Andrew J Portuguese, Ariel F Grajales-Cruz, Andre De Menezes Silva Corraes
Blood Cancer Discovery. 2025-11-03
Press Mentions
CAR-T Destined for Earlier Lines of Therapy in Blood Cancers, Experts SayNovember 18th, 2022
Professional Memberships
- Member
- International Myeloma SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
